Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL)

Journal of Histochemistry and Cytochemistry

Volumn 56, Issue 10, 2008, Pages 893-900

  Talaulikar, Dipti ^a,b   Dahlstrom, Jane Esther ^a,b   Shadbolt, Bruce ^a,b   Broomfield, Amy ^a   McDonald, Anne ^c  

^a CANBERRA HOSPITAL   (Australia)

^b The Australian National University   (Australia)

^c National Capital Private Hospital   (Australia)

Author keywords

Bone marrow trephine biopsy; Diffuse large B cell lymphoma; Histology; Immunohistochemistry; International prognostic index; Staging

Indexed keywords

BIOCHEMICAL MARKER; CD20 ANTIGEN; CD3 ANTIGEN; CD45RO ANTIGEN; CD79A ANTIGEN; EOSIN; HEMATOXYLIN; RETICULIN;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BONE MARROW; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIFFUSE LARGE B CELL LYMPHOMA; FEMALE; GIEMSA STAIN; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OCCULT CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS;

EID: 52949098378     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/jhc.2008.951087     Document Type: Article

References (25)

1. Bain BJ (2001) Bone marrow trephine biopsy. J Clin Pathol 54:737-742
2. Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S (2006) The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol 76:473-480
3. Campbell JK, Matthews JP, Seymour JF, Wolf MM, Juneja SK (2003) Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma. Ann Oncol 14:273-276
4. Chadburn A, Knowles DM (1994) Paraffin-resistant antigens detectable by antibodies L26 and polyclonal CD3 predict the B- or T-cell lineage of 95% of diffuse aggressive non-Hodgkin's lymphomas. Am J Clin Pathol 102:284-291
5. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244
6. Chung R, Lai R, Wei P, Lee J, Hanson J, Belch AR, Turner AR, et al. (2007) Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood 110:1278-1282
7. Conlan MG, Bast M, Armitage JO, Weisenburger DD (1990) Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 8:1163-1172
8. Echeverri C, Fisher S, King D, Craig FE (2002) Immunophenotypic variability of B-cell non-Hodgkin lymphoma: a retrospective study of cases analyzed by flow cytometry. Am J Clin Pathol 117:615-620
9. Fraga M, Brousset P, Schlaifer D, Payen C, Robert A, Rubie H, Huguet-Rigal F, et al. (1995) Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. Am J Clin Pathol 103:82-89
10. Gervasi F, Lo Verso R, Giambanco C, Cardinale G, Tomaselli C, Pagnucco G (2004) Flow cytometric immunophenotyping analysis of patterns of antigen expression in non-Hodgkin's B cell lymphoma in samples obtained from different anatomic sites. Ann NY Acad Sci 1028:457-462
11. Hanson CA, Kurtin PJ, Katzmann JA, Hoyer JD, Li CY, Hodnefield JM, Meyers CH, et al. (1999) Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma. Blood 94:3889-3896
12. Harada S, Suzuki R, Uehira K, Yatabe Y, Kagami Y, Ogura M, Suzuki H, et al. (1999) Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia 13:1441-1447
13. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, et al. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849
14. Horlyck A, Thorling K (1991) Bone marrow examination in non-Hodgkin's lymphoma: comparison of the diagnostic value of marrow aspirations and trephine biopsy. Eur J Haematol 46:54-56
15. Isaacson PG (2007) Haematopathology practice: the commonest problems encountered in a consultation practice. Histopathology 50:821-834
16. Juneja SK, Wolf MM, Cooper IA (1990) Value of bilateral bone marrow biopsy specimens in non-Hodgkin's lymphoma. J Clin Pathol 43:630-632
17. Lossos IS, Morgensztern D (2006) Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 24:995-1007
18. Mazur G, Halon A, Wrobel T, Jelen M, Kuliczkowski K (2004) Contribution of flow cytometric immunophenotyping and bone marrow trephine biopsy in the detection of lymphoid bone marrow infiltration in non-Hodgkin's lymphomas. Neoplasma 51:159-163
19. Miller RT, Swanson PE, Wick MR (2000) Fixation and epitope retrieval in diagnostic immunohistochemistry: a concise review with practical considerations. Appl Immunohistochem Mol Morphol 8:228-235
20. Palacio C, Acebedo G, Navarrete M, Ruiz-Marcellan C, Sanchez C, Blanco A, Lopez A (2001) Flow cytometry in the bone marrow evaluation of follicular and diffuse large B-cell lymphomas. Haematologica 86:934-940
21. Perea G, Altes A, Bellido M, Aventin A, Bordes R, Ayats R, Remacha AF, et al. (2004) Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL). Histopathology 45:268-274
22. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, Cabanillas F, et al. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994
23. Talaulikar D, Shadbolt B, Bell J, Khan K, Dahlstrom JE, McDonald A, Pidcock ME, et al. (2008) Clinical role of flow cytometry in redefining bone marrow involvement in diffuse large B-cell lymphoma (DLBCL): a new perspective. Histopathology 52:340-347
24. Taniguchi M, Oka K, Hiasa A, Yamaguchi M, Ohno T, Kita K, Shiku H (1998) De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation. Blood 91:1145-1151
25. Yan Y, Chan WC, Weisenburger DD, Anderson JR, Bast MA, Vose JM, Bierman PJ, et al. (1995) Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma. J Clin Oncol 13:1336-1342